ETF Managers Group, LLC Contrafect Corp Transaction History

ETF Managers Group, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.79 - $4.45 $1,383 - $2,207	496 Added 4.16%	12,427 $36,000
Q1 2022 May 13, 2022	BUY	$2.26 - $3.84 $94 - $161	42 Added 0.35%	11,931 $44,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $4,979 - $8,346	-2,016 Reduced 14.5%	11,889 $30,000
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $7,279 - $10,109	2,282 Added 19.63%	13,905 $54,000
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $11,112 - $15,209	3,104 Added 36.44%	11,623 $50,000
Q1 2021 May 17, 2021	SELL	$4.46 - $6.68 $22,335 - $33,453	-5,008 Reduced 37.02%	8,519 $38,000
Q4 2020 Feb 16, 2021	SELL	$5.05 - $6.4 $10,448 - $13,241	-2,069 Reduced 13.27%	13,527 $71,000
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $43,536 - $60,260	8,621 Added 123.6%	15,596 $83,000
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $32,712 - $54,474	6,975 New	6,975 $45,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

Stay updated on ETF Managers Group, LLC with notifications on news.